Voyager Therapeutics, Inc. VYGR 深 滬
交易中 08-21 10:41:27 美东时间
3.415
+0.095
+2.86%
華盛通- 最 高3.415
- 今 開3.36
- 成交量 6.04万股
- 最 低 3.315
- 昨 收 3.32
- 總市值 2.10亿
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 2.935
- 委 比 16.50%
- 總股本 6161.79万
- 歷史最高 31.91
- 量 比 0.82
- 振 幅 3.01%
- 歷史最低 2.46
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
08-10 18:58
Voyager Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate, Sales $3.165M Miss $4.728M Estimate
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 29.82 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $3.165 mi...
08-07 06:03
How does Biogen’s novel Alzheimer’s drug compare to approved drugs
While Biogen (BIIB) traded lower after reporting detailed results from a mid-stage trial for its new Alzheimer’s drug, diranersen, developed with Ionis Pharmaceuticals (IONS), patient advocates were u...
07-14 23:26
Voyager Therapeutics advances tau-silencing gene therapy program
Voyager Therapeutics ( ($VYGR) ) has provided an update. On July 13, 2026, Voya...
07-14 01:27
Voyager Therapeutics Presents Six‑Month Toxicology Data At AAIC Showing Investigational Alzheimer’s Gene Therapy VY1706 Was Well Tolerated And Cut Tau Protein Up To 75% In Primates
Voyager Therapeutics Presents Six‑Month Toxicology Data At AAIC Showing Investigational Alzheimer’s Gene Therapy VY1706 Was Well Tolerated And Cut Tau Protein Up To 75% In Primates
07-13 20:10
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics CEO Alfred W. Sandrock Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The webcast will be available on June 15, 2026, at 7:00 a.m. ET on the Company’s investor website and archived for 30 days. Voyager Therapeutics focuses on using human genetics to treat neurological diseases, with programs targeting Alzheimer’s, Parkinson’s, ALS, and...
06-11 20:01
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy
The latest announcement is out from Voyager Therapeutics ( ($VYGR) ). On June 1...
06-01 20:43
Voyager Therapeutics Issued FDA Clearance For Its Investigational New Drug Application For VY1706 To Treat Alzheimer's Disease
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its
06-01 20:02
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics reported positive 3-month GLP toxicology data for VY1706, a tau-silencing gene therapy for Alzheimer's disease, showing up to 64% reduction in tau protein in non-human primates. The IND application for VY1706 is on track for Q2 2026, with clinical trials expected to begin in H2 2026. The company also highlighted advancements in capsid innovation, immune evasion, and manufacturing capabilities across multiple gene therapy prog...
05-13 10:01
